ALLMedicine™ Stem Cell Disorders Center

Nov 25th, 2020 - The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell disorders that are defined by activating mutations in signal transductio...

Sep 4th, 2020 - Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders that may occur after one or more mutations in hematopoietic progenitor cells. In this study, we will review the co-existence of mutations (especially dual ...

Aug 25th, 2020 - Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem cell disorders with an increasing burden on health care systems. Evidence-based MDS guidelines and recommendations (G/Rs) are published but do not necessarily t...

Aug 11th, 2020 - Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders that commonly progress to acute myeloid leukemia (AML). The diagnostics, prognostics, and treatment of adult MDS are established but do not directly tran...

Jul 12th, 2020

Jul 12th, 2020

Feb 2nd, 2021 - Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. MDS may involve one, two, or three myeloid hematopoiesis cell lineages — erythrocytic, granulocytic, megak...

Nov 25th, 2020 - The Philadelphia chromosome negative myeloproliferative neoplasms (MPNs), polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are hematopoietic stem cell disorders that are defined by activating mutations in signal transductio...

Sep 4th, 2020 - Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders that may occur after one or more mutations in hematopoietic progenitor cells. In this study, we will review the co-existence of mutations (especially dual ...

Aug 25th, 2020 - Myelodysplastic syndromes (MDSs) represent a heterogeneous group of hematological stem cell disorders with an increasing burden on health care systems. Evidence-based MDS guidelines and recommendations (G/Rs) are published but do not necessarily t...

Aug 11th, 2020 - Myelodysplastic syndromes (MDS) represent a group of clonal hematopoietic stem cell disorders that commonly progress to acute myeloid leukemia (AML). The diagnostics, prognostics, and treatment of adult MDS are established but do not directly tran...

Feb 2nd, 2021 - Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. MDS may involve one, two, or three myeloid hematopoiesis cell lineages — erythrocytic, granulocytic, megak...

Jul 12th, 2020

Introduction The myelodysplastic and myeloproliferative syndromes are rare in childhood, accounting for about 3% of childhood malignancies.[1] They consist of a heterogeneous group of clonal stem cell disorders characterized by ineffective hematop...